image: Focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, November 17, 2020--COVID-19 can directly cause neurologic symptoms and long-term neurological disease. Elevations of blood biomarkers indicative of brain injury have been reported in the blood and cerebrospinal fluid of COVID-19 patients. Clinical application of blood biomarkers to improve medical management of COVID-19 patients is reported in the peer-reviewed Journal of Neurotrauma. Click here (http://doi.org/10.1089/neu.2020.7332) to read the article now.
"The COVID-19 pandemic poses significant risks for acute and persistent neurological deficits, as well as possible increased risk for neurodegenerative diseases," state Ronald Hayes, PhD, Banyan Biomarkers, and coauthors. "The use of blood biomarkers of brain injury integrated with additional existing diagnostic tools with big dataset analytics could provide timely, cost effective approaches to address this increasingly urgent unmet medical need."
"Although presented in the context of a review article, the manuscript represents so much more," says John Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma. "The paper concisely reviews the increased risks of the COVID-19 patient for persistent neurological deficits, psychiatric disorders, and potential neurodegenerative diseases, while describing mechanisms of the CNS penetrance and action of the virus. The paper provides not only an assessment of the challenges presented by the effects of COVID-19 on the brain, but also provides specific recommendations to address them. In all, this review masterfully argues that many of the technologies needed to probe the effects of the COVID-19 virus on the brain are in hand and can be rapidly applied."
###
About the Journal
Journal of Neurotrauma (https://home.liebertpub.com/publications/journal-of-neurotrauma/39) is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. Journal of Neurotrauma is the official journal of the National Neurotrauma Society (https://www.neurotrauma.org/) and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the Journal of Neurotrauma (https://home.liebertpub.com/publications/journal-of-neurotrauma/39) website.
About the Publisher
Mary Ann Liebert, Inc., publishers (https://www.liebertpub.com/) is known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research. A complete list of the firm's 90 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers (https://www.liebertpub.com/) website.
Journal
Journal of Neurotrauma